Gilead Sciences, Inc. $GILD Shares Bought by Florida Financial Advisors LLC

Florida Financial Advisors LLC raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 25.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 27,073 shares of the biopharmaceutical company’s stock after acquiring an additional 5,419 shares during the quarter. Gilead Sciences makes up approximately 0.9% of Florida Financial Advisors LLC’s investment portfolio, making the stock its 22nd largest position. Florida Financial Advisors LLC’s holdings in Gilead Sciences were worth $3,319,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of GILD. Ares Financial Consulting LLC acquired a new position in Gilead Sciences in the fourth quarter valued at approximately $28,000. Financial Consulate Inc. lifted its holdings in Gilead Sciences by 85.8% in the fourth quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 109 shares during the period. North Star Investment Management Corp. lifted its holdings in Gilead Sciences by 54.8% in the fourth quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 86 shares during the period. BOCHK Asset Management Ltd acquired a new position in Gilead Sciences in the fourth quarter valued at approximately $31,000. Finally, Godfrey Financial Associates Inc. acquired a new position in Gilead Sciences in the fourth quarter valued at approximately $34,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $134.43 on Monday. The stock has a market capitalization of $166.90 billion, a PE ratio of 18.31 and a beta of 0.31. Gilead Sciences, Inc. has a 12 month low of $104.46 and a 12 month high of $157.29. The business has a 50 day simple moving average of $135.30 and a 200-day simple moving average of $134.20. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. The business had revenue of $6.96 billion during the quarter, compared to analysts’ expectations of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The business’s revenue was up 4.4% compared to the same quarter last year. During the same period in the previous year, the business earned $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, analysts anticipate that Gilead Sciences, Inc. will post -0.79 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be given a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 2.4%. The ex-dividend date is Monday, June 15th. Gilead Sciences’s payout ratio is presently 44.69%.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $132.27, for a total transaction of $396,810.00. Following the completion of the sale, the chief financial officer directly owned 173,191 shares in the company, valued at approximately $22,907,973.57. The trade was a 1.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $131.29, for a total value of $3,676,120.00. Following the sale, the insider owned 125,779 shares of the company’s stock, valued at $16,513,524.91. The trade was a 18.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 53,000 shares of company stock worth $7,075,670. 0.30% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

GILD has been the subject of a number of analyst reports. Citigroup boosted their price target on Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a report on Monday, April 13th. TD Cowen boosted their price objective on Gilead Sciences from $145.00 to $160.00 and gave the company a “buy” rating in a research report on Wednesday, February 11th. Wolfe Research boosted their price objective on Gilead Sciences from $155.00 to $170.00 and gave the company an “outperform” rating in a research report on Thursday, February 12th. Wall Street Zen cut Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, Rothschild & Co Redburn cut their price objective on Gilead Sciences from $170.00 to $167.00 in a research report on Monday, May 11th. Twenty-five research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $156.93.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.